Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock about the December 15, 2025 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false and misleading statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, specifically concerning the molecular targets and clinical benefits [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the defendants [5] Legal Process - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3]. Group 3: Clinical Trials and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients, suggesting a competitive advantage for sonelokimab [4]. - Allegations state that the clinical data and Nanobody structure did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies [5] - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide superior clinical benefits [5] - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading statements [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the MoonLake Immunotherapeutics securities class action is from March 10, 2024, to September 29, 2025 [1]. - Investors who purchased common stock during this period may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 15, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake Immunotherapeutics made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically BIMZELX [5]. - Key points of contention include claims about the molecular targets and clinical benefits of SLK, which were allegedly overstated, leading to investor damages when the truth was revealed [5].

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% in one day due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, which is intended to treat moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The lawsuit claims that MoonLake exaggerated SLK's benefits over competitors, particularly in relation to its unique "Nanobody" structure, which was presented as a major competitive advantage [4][6]. Trial Results - The VELA Phase 3 trials, particularly VELA-2, did not meet their primary endpoint, leading to a significant drop in stock price from $61.99 to $6.24, a decrease of $55.75 per share [5]. - Analysts noted that the efficacy results from the successful trial were substantially lower than those achieved by the competitor drug BIMZELX, which shares the same molecular targets [4][6]. Investor Impact - The decline in stock price has prompted Hagens Berman, a plaintiffs' rights firm, to investigate claims of misleading information that may have artificially inflated the stock price during the class period from March 10, 2024, to September 29, 2025 [2][6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a deadline for investors to act by December 15, 2025 [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Allegations and Clinical Data - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [5]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a particular emphasis on dermatology and rheumatology [1]. Class Action Details - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired MoonLake's common stock during this period [1]. Allegations - The complaint outlines several key allegations: - SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F) [3]. - SLK's Nanobody structure does not provide a superior clinical benefit over BIMZELX's monoclonal structure [3]. - The supposed increased tissue penetration of SLK does not translate to clinical efficacy [3]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price dropped significantly [4]. - The stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 15, 2025, and can do so by contacting Rosen Law Firm [4][7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [5]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements achieved [5]. Group 3: Case Allegations - The lawsuit alleges that during the class period, MoonLake made false or misleading statements regarding its product SLK, particularly in comparison to traditional monoclonal antibodies, which led to investor losses when the truth was revealed [6].

Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from March 10, 2024, to September 29, 2025 [3]. - Allegations include that the defendants made materially false statements and failed to disclose critical information about SLK's clinical efficacy compared to BIMZELX [3]. Allegations Against the Company - The complaint states that SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. - It is claimed that SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [3]. - The supposed increased tissue penetration of SLK is alleged not to translate into clinical efficacy [3]. - Defendants are accused of lacking a reasonable basis for their positive statements regarding SLK's superiority to monoclonal antibodies [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].